<DOC>
	<DOCNO>NCT02582996</DOCNO>
	<brief_summary>National clinical trial , phase III , randomize , open , parallel , study superiority , three hundred thirty-six ( 336 ) participant sex , age 18 65 year randomly allocate one two treatment group . The Group 01 use Cefalium® group 02 use Tylenol® .</brief_summary>
	<brief_title>Cefalium® Compared Tylenol® Treatment Migraine Attacks</brief_title>
	<detailed_description>Cefalium® combination Caffeine + Paracetamol + dihydroergotamine mesylate + metoclopramide hydrochloride . The dihydroergotamine mesylate interacts serotonergic , dopaminergic noradrenergic receptor , 's mechanism totally know . The caffeine present mechanism totally clear , may relieve pain activate central noradenosine pathway ( pain suppress system ) . The Metoclopramide hydrochloride present anti-emetic action prokinetic action gastrointestinal tract.One property inhibition nausea vomiting trigger drug ergotamine.Paracetamol , also call acetaminophen effective agent analgesic antipyretic weak anti-inflammatory activity .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subjects gender ; Age older equal 18 young 66 year symptoms migraine headache 50 year age ; Presence migraine headache without aura symptom , least 03 month prior study , criterion define International Classification Headache Disorders ( ICHD ) II , 2004 ( IHS International Headache Society ) Annex I ; Subjects experience 26 migraine attack per month mild moderate pain intensity last 3 month prior screen visit ; Participants able distinguish migraine attack type headache ; Ability understand consent participate clinical research , express signing Informed Consent Form ( ICF ) . Any clinical finding ( clinical evaluation / physical ) interpret Investigator risk subject clinical trial ; Subjects recent episode headache , frequency equal high 15 daily episode per month , 3 month prior screen visit ; Subjects headache history define ICHDII criterion , 2004 IHS ( International Headache Society ) rat : Typical aura nonmigraine headache ; Typical aura without headache ; Familial Hemiplegic Migraine ( FHM ) ; Sporadic Hemiplegic Migraine ; Basilar type Migraine ; Any laboratorial finding Investigator consider risk subject study ; Hypersensitivity drug component use study ; Women pregnancy nursing period ; Women reproductive age agree use contraception acceptable [ oral contraceptive , injectable contraceptive , intrauterine device ( IUD ) , hormonal implant , barrier method , hormonal patch tubal ligation ] ; surgically sterile ( bilateral oophorectomy hysterectomy ) , postmenopausal least one ( 01 ) year sexual abstinence ; Inability understand answer functional categorical scale study , diary symptom , accompany assist him/her ; History abuse , accord principal investigator , alcohol , opioids , barbiturate , benzodiazepine illicit drug last 02 year , abuse drug headache include ergotamine narcotic last 03 month ; Subjects prolong hypotension , shock , sepsis , pheochromocytoma , hemorrhage , mechanical obstruction perforation gastrointestinal tract Participants glucose6phosphate dehydrogenase ( G6PD ) deficiency due increase risk hemolysis associate use paracetamol ; Subjects history epilepsy presence psychiatric illness kind , opinion investigator , may interfere adherence treatment ; Subjects malignant disease less five year , five year , without documentation remission/cure . As example : melanoma , leukemia , lymphoma , myeloproliferative disease renal cell carcinoma length exclude . Exceptions : Participants basal cell skin cancer , squamous cell , cervical cancer situ may eligible ; Subjects use preventive treatment change dose last 02 week screen visit ( V0 ) ; Subjects hepatic renal failure ; Subjects participate clinical trial protocol last twelve ( 12 ) month ( National Board Health Resolution 251 07 August 1997 , Part III , subitem J ) , unless investigator considers may direct benefit ; Subjects prohibit medication describe item 10.2 Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Headache</keyword>
	<keyword>Aura</keyword>
	<keyword>Migraine</keyword>
	<keyword>Moderate Severe</keyword>
</DOC>